{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:19:55Z","timestamp":1792264795384,"version":"4.4.0"},"reference-count":20,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,25]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Belantamab mafodotin (belamaf) combined with standard therapies demonstrated significant progression-free survival (PFS) and overall survival benefits in DREAMM-7 and PFS benefit in DREAMM-8 in relapsed\/refractory multiple myeloma. Belamaf dose modifications managed adverse events, including belamaf-related ocular events. Ocular events included ocular adverse reactions (eg, dry eyes, photophobia, eye irritation) and protocol-mandated ophthalmic examination findings. Protocol-recommended dose modifications for ocular events were driven by ophthalmic examination findings and included belamaf dose delays until resolution and reductions. We used descriptive analyses to evaluate the impact of dose modifications on managing ocular events and treatment efficacy. In patients with normal baseline vision who were receiving treatment, dose modifications extended belamaf dosing intervals to a median of 8 to 12 weeks by 9 months; the prevalences of reduced vision to bilateral 20\/50 or worse and ocular adverse reactions were highest in the first 3 months and remained low at later time points. The median time to resolution after grade \u22652 ophthalmic examination findings was 12 weeks. Rates of belamaf discontinuations due to ocular events were low. Almost all responders (partial response or better) required dose modifications. Most patients achieved a response before an extended (&amp;gt;2 cycles) dose delay; most who had not, subsequently achieved or deepened their response. In DREAMM-7 and DREAMM-8, the median PFS in patients with \u22651 dose delay of \u226512 weeks was 36.6 months and not reached, respectively. Ocular events were common but effectively managed with dose modifications, allowing for patients to remain on treatment and derive robust efficacy benefit. The trials were registered at www.clinicaltrials.gov as #NCT04246047 (DREAMM-7) and #NCT04484623 (DREAMM-8).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016949","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T19:07:06Z","timestamp":1754420826000},"page":"5708-5719","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":22,"title":["Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2390-1218","authenticated-orcid":false,"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"first","affiliation":[{"name":"1Hospital Universitario de Salamanca\/Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca\/Cancer Research Center\/Ciberonc, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Trudel","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4796-3352","authenticated-orcid":false,"given":"Hang","family":"Quach","sequence":"additional","affiliation":[{"name":"3St Vincent's Hospital Melbourne, University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Robak","sequence":"additional","affiliation":[{"name":"4Medical University of \u0141\u00f3d\u017a, \u0141\u00f3d\u017a, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1797-8657","authenticated-orcid":false,"given":"Meral","family":"Beksac","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Liv Hospital Ankara, \u0130stinye University, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludek","family":"Pour","sequence":"additional","affiliation":[{"name":"6Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9036-6625","authenticated-orcid":false,"given":"Marek","family":"Hus","sequence":"additional","affiliation":[{"name":"7Medical University of Lublin, Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5878-8895","authenticated-orcid":false,"given":"Kihyun","family":"Kim","sequence":"additional","affiliation":[{"name":"8Sungkyunkwan University, Samsung Medical Center, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3052-269X","authenticated-orcid":false,"given":"Vera","family":"Zherebtsova","sequence":"additional","affiliation":[{"name":"9Gorodskaya Klinicheskaya Bol\u2019nitsa Im. S.p. Botkina, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sosana","family":"Delimpasi","sequence":"additional","affiliation":[{"name":"10General Hospital Evangelismos, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5467-9253","authenticated-orcid":false,"given":"Tomas","family":"Jel\u00ednek","sequence":"additional","affiliation":[{"name":"11Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Ward","sequence":"additional","affiliation":[{"name":"12The Royal North Shore Hospital, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2811-8671","authenticated-orcid":false,"given":"P. Joy","family":"Ho","sequence":"additional","affiliation":[{"name":"13Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Vorobyev","sequence":"additional","affiliation":[{"name":"14Leningrad Regional Clinical Hospital, Saint Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Pitombeira de Lacerda","sequence":"additional","affiliation":[{"name":"15Universidade da Regi\u00e3o de Joinville and Centro de Hematologia e Oncologia, Joinville, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2598-2760","authenticated-orcid":false,"given":"Gracia","family":"Aparecida-Martinez","sequence":"additional","affiliation":[{"name":"16Hospital das Cl\u00ednicas and Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo, Universidade de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Spicka","sequence":"additional","affiliation":[{"name":"17First Faculty of Medicine, Charles University and General Hospital, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5384-8238","authenticated-orcid":false,"given":"Jakub","family":"Radocha","sequence":"additional","affiliation":[{"name":"184th Department of Internal Medicine \u2013 Hematology, University Hospital Hradec Kr\u00e1lov\u00e9, Faculty of Medicine in Hradec Kr\u00e1lov\u00e9, Charles University, Hradec Kr\u00e1lov\u00e9, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[{"name":"19Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9104-5436","authenticated-orcid":false,"given":"Claudio","family":"Cerchione","sequence":"additional","affiliation":[{"name":"20Hematology Unit, Istituto Romagnolo per lo Studio dei Tumori \"Dino Amadori,\" Istituto di Ricovero e Cura a Carattere Scientifico, Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengcheng","family":"Fu","sequence":"additional","affiliation":[{"name":"21The First Affiliated Hospital of Soochow University, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0300-378X","authenticated-orcid":false,"given":"Kazuhito","family":"Suzuki","sequence":"additional","affiliation":[{"name":"22Division of Clinical Oncology\/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Rogers","sequence":"additional","affiliation":[{"name":"23GSK, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Phillips-Jones","sequence":"additional","affiliation":[{"name":"24GSK, Stevenage, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Wang","sequence":"additional","affiliation":[{"name":"23GSK, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hena","family":"Baig","sequence":"additional","affiliation":[{"name":"25GSK, Mississauga, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodie","family":"Wilkes","sequence":"additional","affiliation":[{"name":"24GSK, Stevenage, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoou L.","family":"Zhou","sequence":"additional","affiliation":[{"name":"26GSK, Waltham, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Lewis","sequence":"additional","affiliation":[{"name":"27GSK, Research Triangle Park, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2555-0725","authenticated-orcid":false,"given":"Lydia","family":"Eccersley","sequence":"additional","affiliation":[{"name":"28GSK, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5724-7942","authenticated-orcid":false,"given":"Neal","family":"Sule","sequence":"additional","affiliation":[{"name":"23GSK, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prani","family":"Paka","sequence":"additional","affiliation":[{"name":"23GSK, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna B.","family":"Opalinska","sequence":"additional","affiliation":[{"name":"23GSK, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pralay","family":"Mukhopadhyay","sequence":"additional","affiliation":[{"name":"23GSK, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4327-1957","authenticated-orcid":false,"given":"Vania","family":"Hungria","sequence":"additional","affiliation":[{"name":"29Cl\u00ednica S\u00e3o Germano, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios Athanasios","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"30Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"},{"name":"31Department of Medicine, Korea University, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"issue":"5","key":"2025112509012770100_bib1","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa2405090","article-title":"Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma","volume":"391","author":"Hungria","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"2025112509012770100_bib2","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2403407","article-title":"Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma","volume":"391","author":"Dimopoulos","year":"2024","journal-title":"N Engl J Med"},{"key":"2025112509012770100_bib3","author":"Hungria","year":"7-10  2024"},{"issue":"2","key":"2025112509012770100_bib4","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41591-023-02703-y","article-title":"Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1\/2 trial","volume":"30","author":"Trudel","year":"2024","journal-title":"Nat Med"},{"issue":"suppl 1","key":"2025112509012770100_bib5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood-2020-139332","article-title":"DREAMM-6: safety, tolerability and clinical activity of belantamab mafodotin (belamaf) in combination with bortezomib\/dexamethasone (bordex) in relapsed\/refractory multiple myeloma (RRMM) [abstract]","volume":"136","author":"Popat","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2025112509012770100_bib6","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","article-title":"BCMA-targeted immunotherapy for multiple myeloma","volume":"13","author":"Yu","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"8","key":"2025112509012770100_bib7","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1158\/0008-5472.CAN-17-3202","article-title":"Modulation of macropinocytosis-mediated internalization decreases ocular toxicity of antibody-drug conjugates","volume":"78","author":"Zhao","year":"2018","journal-title":"Cancer Res"},{"issue":"4","key":"2025112509012770100_bib8","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","article-title":"Corneal epithelial findings in patients with multiple myeloma treated with antibody-drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study [published correction appears in Ophthalmol Ther. 2020;9(4):913-915]","volume":"9","author":"Farooq","year":"2020","journal-title":"Ophthalmol Ther"},{"issue":"10","key":"2025112509012770100_bib9","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/jop.2015.0064","article-title":"Ocular adverse events associated with antibody-drug conjugates in human clinical trials","volume":"31","author":"Eaton","year":"2015","journal-title":"J Ocul Pharmacol Ther"},{"issue":"5","key":"2025112509012770100_bib10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41408-021-00494-4","article-title":"Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)","volume":"11","author":"Lonial","year":"2021","journal-title":"Blood Cancer J"},{"issue":"8","key":"2025112509012770100_bib11","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"2025112509012770100_bib12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2307\/2530286","article-title":"The confidence interval for the median survival time","volume":"38","author":"Brookmeyer","year":"1982","journal-title":"Biometrics"},{"issue":"22","key":"2025112509012770100_bib13","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1002\/cncr.33809","article-title":"Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study","volume":"127","author":"Lonial","year":"2021","journal-title":"Cancer"},{"issue":"suppl 1","key":"2025112509012770100_bib14","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1182\/blood-2023-178009","article-title":"Impact of long-term treatment with belantamab mafodotin on safety and efficacy outcomes in patients with relapsed\/refractory multiple myeloma in DREAMM-3 [abstract]","volume":"142","author":"Hungria","year":"2023","journal-title":"Blood"},{"issue":"10","key":"2025112509012770100_bib15","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1158\/1535-7163.MCT-21-0035","article-title":"Belantamab mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated antitumor responses in vivo","volume":"20","author":"Montes de Oca","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"2025112509012770100_bib16","author":"Dimopoulos","year":"25-28  2024"},{"issue":"suppl 16","key":"2025112509012770100_bib17","doi-asserted-by":"crossref","first-page":"7543","DOI":"10.1200\/JCO.2024.42.16_suppl.7543","article-title":"Patient-reported outcomes (PROs) from the DREAMM-7 randomized phase 3 study comparing belantamab mafodotin, bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed\/refractory multiple myeloma (RRMM) [abstract]","volume":"42","author":"Hungria","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025112509012770100_bib18","unstructured":"A study of belantamab mafodotin administered in combination with lenalidomide and dexamethasone (BRd) versus daratumumab, lenalidomide, and dexamethasone (DRd) in participants with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplantation (TI-NDMM) (DREAMM-10). ClinicalTrials.gov identifier: NCT06679101. Updated 6 August 2025. Accessed 18 March 2025. https:\/\/clinicaltrials.gov\/study\/NCT06679101."},{"key":"2025112509012770100_bib19","unstructured":"A study to investigate the safety and efficacy of belantamab for the treatment of multiple myeloma when used as monotherapy and in combination treatments (DREAMM-20). ClinicalTrials.gov identifier: NCT05714839. Updated 5 June 2025. Accessed 9 April 2025. https:\/\/clinicaltrials.gov\/study\/NCT05714839."},{"issue":"suppl 16","key":"2025112509012770100_bib20","article-title":"Design of the phase 3 DREAMM-10 study: belantamab mafodotin plus lenalidomide and dexamethasone (BRd) vs daratumumab plus lenalidomide and dexamethasone (DRd) in transplant-ineligible, newly diagnosed multiple myeloma (TI-NDMM) [abstract]","volume":"43","author":"Lonial","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/22\/5708\/2419931\/blooda_adv-2025-016949-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/22\/5708\/2419931\/blooda_adv-2025-016949-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T14:01:34Z","timestamp":1764079294000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/22\/5708\/546495\/Modification-of-belantamab-mafodotin-dosing-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":20,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2025,11,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016949","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11,25]]},"published":{"date-parts":[[2025,11,12]]}}}